External Controls: Sarepta’s DMD Gene Therapy Not In the Same Boat As Zolgensma, US FDA Says

Looking out window
Sarepta looked outside the SRP-9001 clinical program to contextualize the gene therapy's clinical efficacy results. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers